Updated numbers on STAMPEDE trial

[snoraste]

This is a very detailed follow up report at 78month for STAMPEDE. Probably worth a read.

academic.oup.com/annonc/art...

[timotur]

Thanks for posting, very informative... One thing not apparent in the reading is the definition of high- vs low-burden metastasis, which they refer to as per the CHAARTED definition. I will have to look that up, but I believe HIGH is any TWO of (1) G>= 8, (2) more than three bone mets, or (3) visceral mets.

[marnieg46 in reply to timotur]

Hi timotur, I think you might find your answer here....

urotoday.com/video-lectures...

[timotur in reply to marnieg46]

Thank you, looking at your link and reading a summary of CHAARTED it looks like the definition is:

(1) High-volume disease was defined as presence of visceral metastases and/or ≥ four bone metastases with at least one outside of the vertebral column and pelvis,

and I assume, (2) low-volume is 1-3 mets and all mets within the vertebral axis.

So, that means N1 patients are not differentiated in STAMPEDE or CHAARTED, only M1 with bone mets acc to how many and where.

ncbi.nlm.nih.gov/pmc/articl...

The gentleman in the video is basically saying CHAARTED differentiated a benefit acc to volume (i.e. chemo only benefited high-vol), whereas the newly released data in STAMPEDE did not, (i.e. chemo benefited both groups).